Related Experiment Video

Updated: May 3, 2026

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

3.8K

Cancer progression and substance P

Rafael Coveñas1, Miguel Muñoz2

  • 1Institute of Neurosciences of Castilla y León (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems, University of Salamanca, Salamanca, Spain.

Histology and Histopathology
|February 19, 2014
PubMed

Insights

The substance P (SP) and neurokinin (NK)-1 receptor system drives cancer growth. Targeting this system with NK-1 receptor antagonists, like aprepitant, inhibits tumor proliferation and metastasis, offering a promising cancer treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The substance P (SP)/neurokinin (NK)-1 receptor system is implicated in cancer progression.
  • SP binding to NK-1 receptors promotes tumor cell proliferation, migration, and angiogenesis.

Purpose of the Study:

  • To investigate the role of the SP/NK-1 receptor system in cancer.
  • To evaluate NK-1 receptor antagonists as a potential cancer therapy.

Main Methods:

  • Review of existing literature on SP/NK-1 receptor signaling in cancer.
  • Analysis of the effects of NK-1 receptor antagonists on tumor cell behavior.

Main Results:

  • NK-1 receptor antagonists inhibit tumor cell proliferation via apoptosis.
  • These antagonists also block tumor cell migration and possess antiangiogenic properties.
  • The NK-1 receptor antagonist aprepitant demonstrates antitumor activity in various human tumor cells.

Conclusions:

  • The NK-1 receptor is a viable therapeutic target for cancer treatment.
  • NK-1 receptor antagonists show potential as broad-spectrum antineoplastic agents.
  • Further clinical trials are warranted to validate the antitumor efficacy of aprepitant.

More Related Videos

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

2.0K
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

978

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Tumor Progression02:07

Tumor Progression

3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K